Associated cancers in Waldenström macroglobulinemia: Clues for common genetic predisposition

Enrica Morra, Marzia Varettoni, Alessandra Tedeschi, Luca Arcaini, Francesca Ricci, Cristiana Pascutto, Sara Rattotti, Eleonora Vismara, Laura Paris, Mario Cazzola

Research output: Contribution to journalArticle

Abstract

Background Several population-based and cohort studies have reported an increased risk of second cancers in lymphoproliferative disorders (LPDs). The cause of second cancers in LPDs is probably multifactorial, and the relative contribution of treatments, genetic predisposition, and immune dysfunction typical of LPDs is still unclear. Patients and Methods We retrospectively studied 230 patients with Waldenström macroglobulinemia (WM) to assess the frequency, characteristics, and predictive factors of second cancers and to evaluate whether patients with WM are at higher risk of second cancers compared with an age- and sex-matched control population. Results In a competing-risk model, the cumulative incidence of solid cancers was 6% at 5 years, 11% at 10 years, and 17% at 15 years, whereas the incidence of hematologic malignancies was 4% at 5 years, 7% at 10 years, and 8% at 15 years. Compared with an age- and sex-matched population, the overall risk of second cancers was 1.7-fold higher than expected (95% confidence interval [CI], 1.22-2.38; P =.002). Patients with WM were at increased risk for diffuse large B-cell lymphoma (DLBCL) (standardized incidence ratio [SIR], 8.64; 95% CI, 3.88-19.22; P

Original languageEnglish
Pages (from-to)700-703
Number of pages4
JournalClinical Lymphoma, Myeloma and Leukemia
Volume13
Issue number6
DOIs
Publication statusPublished - Dec 2013

Fingerprint

Waldenstrom Macroglobulinemia
Second Primary Neoplasms
Genetic Predisposition to Disease
Lymphoproliferative Disorders
Neoplasms
Incidence
Confidence Intervals
Population
Lymphoma, Large B-Cell, Diffuse
Hematologic Neoplasms
Cohort Studies

Keywords

  • Hematologic malignancies
  • Second cancers
  • Solid tumors
  • Waldenström macroglobulinemia

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Associated cancers in Waldenström macroglobulinemia : Clues for common genetic predisposition. / Morra, Enrica; Varettoni, Marzia; Tedeschi, Alessandra; Arcaini, Luca; Ricci, Francesca; Pascutto, Cristiana; Rattotti, Sara; Vismara, Eleonora; Paris, Laura; Cazzola, Mario.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 13, No. 6, 12.2013, p. 700-703.

Research output: Contribution to journalArticle

Morra, Enrica ; Varettoni, Marzia ; Tedeschi, Alessandra ; Arcaini, Luca ; Ricci, Francesca ; Pascutto, Cristiana ; Rattotti, Sara ; Vismara, Eleonora ; Paris, Laura ; Cazzola, Mario. / Associated cancers in Waldenström macroglobulinemia : Clues for common genetic predisposition. In: Clinical Lymphoma, Myeloma and Leukemia. 2013 ; Vol. 13, No. 6. pp. 700-703.
@article{8b9ba4afac43418f8f6abd0767c9f5a7,
title = "Associated cancers in Waldenstr{\"o}m macroglobulinemia: Clues for common genetic predisposition",
abstract = "Background Several population-based and cohort studies have reported an increased risk of second cancers in lymphoproliferative disorders (LPDs). The cause of second cancers in LPDs is probably multifactorial, and the relative contribution of treatments, genetic predisposition, and immune dysfunction typical of LPDs is still unclear. Patients and Methods We retrospectively studied 230 patients with Waldenstr{\"o}m macroglobulinemia (WM) to assess the frequency, characteristics, and predictive factors of second cancers and to evaluate whether patients with WM are at higher risk of second cancers compared with an age- and sex-matched control population. Results In a competing-risk model, the cumulative incidence of solid cancers was 6{\%} at 5 years, 11{\%} at 10 years, and 17{\%} at 15 years, whereas the incidence of hematologic malignancies was 4{\%} at 5 years, 7{\%} at 10 years, and 8{\%} at 15 years. Compared with an age- and sex-matched population, the overall risk of second cancers was 1.7-fold higher than expected (95{\%} confidence interval [CI], 1.22-2.38; P =.002). Patients with WM were at increased risk for diffuse large B-cell lymphoma (DLBCL) (standardized incidence ratio [SIR], 8.64; 95{\%} CI, 3.88-19.22; P",
keywords = "Hematologic malignancies, Second cancers, Solid tumors, Waldenstr{\"o}m macroglobulinemia",
author = "Enrica Morra and Marzia Varettoni and Alessandra Tedeschi and Luca Arcaini and Francesca Ricci and Cristiana Pascutto and Sara Rattotti and Eleonora Vismara and Laura Paris and Mario Cazzola",
year = "2013",
month = "12",
doi = "10.1016/j.clml.2013.05.008",
language = "English",
volume = "13",
pages = "700--703",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",
number = "6",

}

TY - JOUR

T1 - Associated cancers in Waldenström macroglobulinemia

T2 - Clues for common genetic predisposition

AU - Morra, Enrica

AU - Varettoni, Marzia

AU - Tedeschi, Alessandra

AU - Arcaini, Luca

AU - Ricci, Francesca

AU - Pascutto, Cristiana

AU - Rattotti, Sara

AU - Vismara, Eleonora

AU - Paris, Laura

AU - Cazzola, Mario

PY - 2013/12

Y1 - 2013/12

N2 - Background Several population-based and cohort studies have reported an increased risk of second cancers in lymphoproliferative disorders (LPDs). The cause of second cancers in LPDs is probably multifactorial, and the relative contribution of treatments, genetic predisposition, and immune dysfunction typical of LPDs is still unclear. Patients and Methods We retrospectively studied 230 patients with Waldenström macroglobulinemia (WM) to assess the frequency, characteristics, and predictive factors of second cancers and to evaluate whether patients with WM are at higher risk of second cancers compared with an age- and sex-matched control population. Results In a competing-risk model, the cumulative incidence of solid cancers was 6% at 5 years, 11% at 10 years, and 17% at 15 years, whereas the incidence of hematologic malignancies was 4% at 5 years, 7% at 10 years, and 8% at 15 years. Compared with an age- and sex-matched population, the overall risk of second cancers was 1.7-fold higher than expected (95% confidence interval [CI], 1.22-2.38; P =.002). Patients with WM were at increased risk for diffuse large B-cell lymphoma (DLBCL) (standardized incidence ratio [SIR], 8.64; 95% CI, 3.88-19.22; P

AB - Background Several population-based and cohort studies have reported an increased risk of second cancers in lymphoproliferative disorders (LPDs). The cause of second cancers in LPDs is probably multifactorial, and the relative contribution of treatments, genetic predisposition, and immune dysfunction typical of LPDs is still unclear. Patients and Methods We retrospectively studied 230 patients with Waldenström macroglobulinemia (WM) to assess the frequency, characteristics, and predictive factors of second cancers and to evaluate whether patients with WM are at higher risk of second cancers compared with an age- and sex-matched control population. Results In a competing-risk model, the cumulative incidence of solid cancers was 6% at 5 years, 11% at 10 years, and 17% at 15 years, whereas the incidence of hematologic malignancies was 4% at 5 years, 7% at 10 years, and 8% at 15 years. Compared with an age- and sex-matched population, the overall risk of second cancers was 1.7-fold higher than expected (95% confidence interval [CI], 1.22-2.38; P =.002). Patients with WM were at increased risk for diffuse large B-cell lymphoma (DLBCL) (standardized incidence ratio [SIR], 8.64; 95% CI, 3.88-19.22; P

KW - Hematologic malignancies

KW - Second cancers

KW - Solid tumors

KW - Waldenström macroglobulinemia

UR - http://www.scopus.com/inward/record.url?scp=84887995079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887995079&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2013.05.008

DO - 10.1016/j.clml.2013.05.008

M3 - Article

C2 - 24070824

AN - SCOPUS:84887995079

VL - 13

SP - 700

EP - 703

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

IS - 6

ER -